Ignite Creation Date:
2024-05-06 @ 6:43 PM
Last Modification Date:
2024-10-26 @ 2:53 PM
Study NCT ID:
NCT05766449
Status:
RECRUITING
Last Update Posted:
2023-03-13
First Post:
2023-02-21
Brief Title:
Risk Factors for Hepatic Inflammation Fibrosis and Prognosis in Patients With CHB and NAFLD
Sponsor:
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Organization:
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Study Overview
Official Title:
Risk Factors for Hepatic Inflammation Fibrosis and Prognosis in Patients With Chronic Hepatitis B Combined With Non-alcoholic Fatty Liver Disease
Status:
RECRUITING
Status Verified Date:
2023-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Chronic hepatitis B CHB affects an estimated 292 million people and causes approximately 800000 people deaths per year from liver-related complications including cirrhosis and hepatocellular carcinoma remaining a major global public health issueMeanwhile with the improvement of living standards and changes in lifestyle and dietary habits non-alcoholic fatty liver disease NAFLD has become another important cause of liver cirrhosis and HCCHBV combined with NAFLD inevitably develops into continuous or intermittent liver inflammation and fibrosis which greatly increases the risk of cirrhosis liver cancer and even end-stage liver disease We aimed to investigate the risk factors and establish diagnostic models for hepatic inflammation fibrosis in patients with CHB associated NAFLD In addition to find risk factors for liver cirrhosis liver cancer or liver failure in patients with CHB-related NAFLD
Detailed Description:
Chronic hepatitis B CHB affects an estimated 292 million people and causes approximately 800000 people deaths per year from liver-related complications including cirrhosis and hepatocellular carcinoma remaining a major global public health issueMeanwhile with the improvement of living standards and changes in lifestyle and dietary habits non-alcoholic fatty liver disease NAFLD has become another important cause of liver cirrhosis and HCCHBV combined with NAFLD inevitably develops into continuous or intermittent liver inflammation and fibrosis which greatly increases the risk of cirrhosis liver cancer and even end-stage liver disease We aimed to investigate the risk factors and establish diagnostic models of hepatic inflammation and fibrosis in CHB associated NAFLD patients using a multicenter study In addition to find risk factors for liver cirrhosis liver cancer or liver failure in patients with CHB-related NAFLD
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None